TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the second quarter of fiscal year 2026.
Core revenue of JPY663.3 billion (+14.7%), core operating profit of JPY329.1 billion (+21.0%), and core net income of JPY238.4 billion (+23.2%) were achieved (all changes year-on-year)
Strong growth in domestic and overseas sales, combined with a significant increase in other revenue driven by one-time income, and royalty income related to Hemlibra and NEMLUVIO, resulted in increased revenue and profit year-on-year
Achieved eight regulatory filings in Japan during the first half of the year, progressing steadily toward achieving the highest number of filings ever planned
R&D activities progressed steadily across both early- and late-stage development, including Chugai-originated projects
For NXT007, which is expected to become a next-generation growth driver, two Phase III studies were initiated
For AQUA07, the third macrocyclic peptide project, entry into the clinical stage was achieved, with dosing in a Phase I study in ALK-positive non-small cell lung cancer expected to start shortly
For Enspryng, developed using Chugai's proprietary antibody engineering technologies, the U.S. FDA accepted the regulatory application for thyroid eye disease (TED) and granted Priority Review designation
Regarding products out-licensed to third parties, global market penetration of Chugai-originated new products advanced
Export sales and royalty income from NEMLUVIO (nemolizumab), a humanized anti-human IL-31 receptor A monoclonal antibody out-licensed to Galderma, drove revenue growth
As for Foundayo (orforglipron), an oral GLP-1 receptor agonist out-licensed to Eli Lilly, prescriptions were driven in the U.S. primarily by GLP-1 naive patients, and the oral anti-obesity drug market is expanding. Chugai commenced recognition of royalty income from the product in the second quarter
Contact:
Naoki Kouzai
Tel: +81-3-3273-0881
Email: pr@chugai-pharm.co.jp
Takayuki Sakurai
Tel: +81-3-3273-0554
Email: ir@chugai-pharm.co.jp
(C) 2026 Electronic News Publishing, source ENP Newswire